Aurora Cannabis Inc. is open to considering an acquisition offer from a U.S. cannabis company looking to take over the Edmonton-based company. The announcement of forming a special committee to review the unsolicited bid came shortly after Curaleaf Holdings Inc. disclosed its intention to acquire all shares of Aurora.
If successful, the acquisition would result in a merged cannabis entity operating in 17 countries across Europe, North America, and other global markets, as stated by Curaleaf. The Connecticut-based company, traded on the Toronto Stock Exchange, decided to publicly announce its bid after unsuccessful attempts to negotiate with Aurora privately.
Curaleaf mentioned that Aurora’s board declined to engage in discussions following the submission of a formal letter of intent by Curaleaf’s CEO on June 23. Despite a follow-up letter sent on July 7, Aurora reportedly did not participate in constructive talks. Curaleaf expressed disappointment in Aurora’s lack of engagement and emphasized its readiness to swiftly proceed towards a definitive agreement.
The proposed offer from Curaleaf suggests paying Aurora shareholders $4 US per share, alongside an additional $0.75 US in cash for each Aurora share. Aurora acknowledged receiving the letters from Curaleaf outlining the proposals but disputed Curaleaf’s claim of refusal to engage, citing ongoing communication between the companies’ leadership.
Aurora has decided to establish a special committee of independent directors to evaluate the proposal’s alignment with stakeholders’ interests. However, the company cautioned that a final agreement is not guaranteed, and operations will continue as usual in the interim.
While Curaleaf’s interest in the acquisition is viewed positively, analysts from TD Cowen believe that the current offer undervalues Aurora’s long-term potential and market position in the medical cannabis sector. They highlighted Aurora’s leadership, product portfolio, financial stability, and regulatory expertise as factors contributing to substantial future value creation.
Curaleaf’s CEO emphasized the potential value creation through a merger, citing the combination of Curaleaf’s global distribution network with Aurora’s medical cannabis expertise and production capabilities. The companies’ combined revenue exceeded $1.5 billion US in the past year, with Curaleaf anticipating significant annual cost synergies from the proposed acquisition.
The proposed deal is seen as mutually beneficial for both Curaleaf and Aurora shareholders, offering an opportunity to partake in a diversified global platform and leverage U.S. regulatory trends, as stated by Curaleaf’s CEO.